Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of $0.73, $0.75 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $413.5 million versus the consensus estimate of $379.15 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.